Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity



Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar... | June 5, 2023

Related Keywords

United States ,American , ,Mary Crowley Research ,Twitter ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Steveno Day ,Chief Medical Officer ,Antibody Designed ,Avoid Hepatoxicity ,Advanced Solid Tumors ,Minal Barve ,Executive Director ,Agenus Inc Stock Exchange ,News ,Information ,Press Release ,Gen2373 ,Us ,The ,First ,D137 ,Agonist ,Ntibody ,Reporting ,Single ,Agent ,Responses ,Ith ,O ,Major ,Eported ,N ,Patients ,Prostate ,Mpullary ,Arcinoma ,End ,Etastatic Agen Us00847g7051 ,